Compare Fastenal Company Common Stock (FAST) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastenal Company Common Stock vs Repligen Corporation Common Stock — how do they compare? Fastenal Company Common Stock trades at $52.23 (market cap $59.02B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: Fastenal Company Common Stock is far larger — about 5.3× Repligen Corporation Common Stock's market cap, and Fastenal Company Common Stock pays a 1.87% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fastenal Company Common Stock for 2 Days and Repligen Corporation Common Stock for 0 Days on average.
| FAST | RGEN | |
|---|---|---|
Market Cap | $59.02B | $11.14B |
Volume | 10,054,911 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $52.38 | $194.57 |
52-Week Low | $39.15 | $102.87 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $59.25B | $11.02B |
Dividend Yield | 1.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastenal (FAST) trades at $51.43, down 0.12% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q3 2026 earnings of $0.35 per share beating estimates, marking the fourth consecutive quarterly beat. Revenue grew 15.5% year-over-year to $2.46 billion, driven by market share gains and new contract wins. The stock shows resilience with consistent operational performance despite premium valuation metrics.
Outlook remains positive with strong industrial demand and digital initiatives supporting growth, though the elevated P/E ratio of 43.96 presents valuation risk. Analyst consensus leans cautious with 59% hold ratings, suggesting limited near-term upside from current levels. Key risks include economic sensitivity and competitive pressures in industrial distribution.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastenal Company Common Stock
Fastenal distributes fasteners, tools, safety supplies, and other industrial products. It also provides inventory management and vending solutions for business customers.
Read more on FAST →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
